ClinicalTrials.gg

Program

rilvegostomig

Also written as “Rilvegostomig”, “AZD2936” and “AZD9592 + Rilvegostomig”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Biliary Tract Neoplasms · Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Furthest: phase 3, since Oct 26, 202324 company-led studies, 23 open or runningNext primary completion: May 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2222 open or runningphase 3since Oct 26, 2023Dec 13, 2018May 4, 2027phase 2 · NCT04379596
Presage Biosciences21 open or runningearly phase 1since Sep 1, 2020Sep 1, 2020Dec 2031early phase 1 · NCT04541108
  • Named in AstraZeneca’s own pipeline as rilvegostomig, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Dec 13, 2018.

  1. Oct 26, 2023Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06109779 · 760 enrolled · United States, Australia, Belgium and more
  2. Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckPresage Biosciences · NCT06366451 · 17 enrolled · United States
  3. Apr 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06357533 · 675 planned · United States, Australia, Austria and more
  4. May 21, 2024Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06467357 · 620 planned · United States, Australia, Austria and more
  5. Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06564844 · 25 enrolled · United States, Brazil, Canada and more
  6. Oct 3, 20242 phase 3 studiesAstraZeneca · NCT06627647, NCT06692738
  7. Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerAstraZeneca · NCT06764875 · 840 planned · United States, Argentina, Australia and more
  8. Mar 7, 20253 phase 3 studiesAstraZeneca · NCT06868277, NCT06989112, NCT06921785
  9. May 5, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06996782 · 152 planned · United States, Belgium, Brazil and more
  10. Sep 3, 2025Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyAstraZeneca · NCT07161414 · 40 planned · United States, South Korea, Spain and more
  11. Oct 1, 2025Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT07221253 · 1,100 planned · United States, Australia, Belgium and more
  12. Jan 16, 2026Phase 3 study in Stomach NeoplasmsAstraZeneca · NCT07431281 · 2,130 planned · United States, Australia, Austria and more
  13. Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellAstraZeneca · NCT07720284 · 915 planned · United States, Australia, Brazil and more
  14. Nov 10, 2026Primary completion moved from 2026-08-28 to 2028-06-01Date moved laterphase 2 · +21 months · NCT04995523

Ahead

  1. May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT04379596
  2. Jul 19, 2027Primary completion: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyAstraZeneca · NCT07161414
  3. Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsAstraZeneca · NCT05123482
  4. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229

TargetBeta

“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory …”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory mot”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more3RecruitingAstraZenecaSep 11, 2030915
NCT07431281Stomach Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaAug 16, 20292,130
NCT07221253Biliary Tract Neoplasms · United States, Australia, Belgium and more3RecruitingAstraZenecaJul 31, 20291,100
NCT07161414Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, South Korea, Spain and more1RecruitingAstraZenecaJul 19, 202740
NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more2RecruitingAstraZenecaFeb 23, 2029152
NCT06921785Carcinoma, Hepatocellular · United States, Australia, Brazil and more3RecruitingAstraZenecaMar 15, 20301,220
NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaJan 19, 2029600
NCT06868277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingAstraZenecaJan 17, 2030830
NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more3RecruitingAstraZenecaApr 27, 2029840
NCT06692738Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingAstraZenecaJul 1, 20301,160
NCT06627647Non-squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more3RecruitingAstraZenecaNov 18, 20301,160
NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more3Active, not recruitingAstraZenecaJul 10, 202625
NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaJun 12, 2028620
NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingAstraZenecaDec 28, 2029675
NCT06366451Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1CompletedPresage BiosciencesMar 25, 202617
NCT06109779Biliary Tract Neoplasms · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaJan 2, 2029760
NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more2Active, not recruitingAstraZenecaOct 27, 2026294
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingAstraZenecaNov 30, 2027163
NCT05123482Breast Neoplasms · United States, Australia, Belgium and more2RecruitingAstraZenecaSep 29, 2027460
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingAstraZenecaMay 28, 2030630
NCT04995523Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2Active, not recruitingAstraZenecaJun 1, 2028212
NCT04541108Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1Active, not recruitingPresage BiosciencesDec 203115
NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more2Active, not recruitingAstraZenecaMay 4, 2027452
NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more1Active, not recruitingAstraZenecaMay 23, 2023175

How it is read

Names in the registry

  • “Rilvegostomig”, 20 entries
  • “AZD2936”, 2 entries
  • “AZD9592 + Rilvegostomig”, 2 entries
  • “AZD8205 and AZD2936 (Rilvegostomig)”, 1 entry
  • “AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.